Bridgeway Capital Management’s Annovis Bio ANVS Stock Holding History

Bridgeway Capital Management’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$84K	Buy	37,677 +13,277	+54%	+$36.4K	﹤0.01%	1142
2025 Q4	$84.4K	Buy	24,400 +5,000	+26%	+$15K	﹤0.01%	1148
2025 Q3	$40.2K	Hold	19,400	–	–	﹤0.01%	1175
2025 Q2	$42.1K	Hold	19,400	–	–	﹤0.01%	1140
2025 Q1	$29.1K	Sell	19,400 -2,000	-9%	-$6.12K	﹤0.01%	1145
2024 Q4	$108K	Sell	21,400 -700	-3%	-$5.07K	﹤0.01%	1102
2024 Q3	$178K	Hold	22,100	–	–	﹤0.01%	1090
2024 Q2	$127K	Sell	22,100 -11,500	-34%	-$93.2K	﹤0.01%	1138
2024 Q1	$400K	Buy	33,600 +10,000	+42%	+$109K	0.01%	981
2023 Q4	$441K	Hold	23,600	–	–	0.01%	971
2023 Q3	$224K	Hold	23,600	–	–	0.01%	1077
2023 Q2	$337K	Hold	23,600	–	–	0.01%	1017
2023 Q1	$364K	Hold	23,600	–	–	0.01%	959
2022 Q4	$317K	Hold	23,600	–	–	0.01%	976
2022 Q3	$323K	Hold	23,600	–	–	0.01%	1016
2022 Q2	$268K	Hold	23,600	–	–	0.01%	1024
2022 Q1	$315K	Hold	23,600	–	–	0.01%	1063
2021 Q4	$415K	Hold	23,600	–	–	0.01%	1030
2021 Q3	$749K	Hold	23,600	–	–	0.01%	914
2021 Q2	$2.02M	Buy	23,600 +1,100	+5%	+$50.8K	0.04%	631
2021 Q1	$628K	Buy	+22,500	New	+$481K	0.01%	1033

Other funds holding ANVS

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Bridgeway Capital Management's ANVS Position: Q1 2026 in Review

Bridgeway Capital Management increased its Annovis Bio (ANVS) stake by 54% in Q1 2026, buying an estimated $36.4K and bringing the position to 37,677 shares worth $84K. The position accounts for ﹤0.01% of the portfolio, ranked #1142.

Bridgeway Capital Management first reported a position in ANVS in Q1 2021 and has held it in 21 quarters since. The position peaked at $2.02M in Q2 2021. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

Bridgeway Capital Management held 37,677 shares of Annovis Bio worth $84K as of Q1 2026.
Bridgeway Capital Management bought 13,277 Annovis Bio shares in Q1 2026, an estimated $36.4K.
Annovis Bio made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1142 holding.
Bridgeway Capital Management first reported a position in Annovis Bio in Q1 2021 and has held it in 21 quarters since.
Bridgeway Capital Management's Annovis Bio position peaked at $2.02M in Q2 2021.
56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.